AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32277344
Drug: Two-step infusion
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step infusion of imipenem (1.0 g q8h)
Trial: 33413049
Drug: AMCAFF (caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMCAFF (caffeine 3 mg/kg in the morning)
Trial: 32900336
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of therapy until target pH is achieved
Trial: 34267156
Drug: 7.5% hypertonic
RxNorm normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% hypertonic saline (HTS) (2 mL/kg)
Trial: 34267156
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol (4.6 mL/kg)
Trial: 38902928
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocortisone
Trial: 38902928
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg yohimbine
Trial: 33860721
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocortisone/10 mg yohimbine combined
Trial: 34719711
Drug: Palliative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative care screening tool administered daily for 8 weeks
Trial: 33811649
Drug: Group counseling
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group counseling based on the solution-focused approach (SFA)
Trial: 32741505
Drug: Integrated Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Cognitive Behavioral Treatment (I-CBT)
Trial: 33475138
Drug: Sitagliptin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin + insulin (SITA)
Trial: 32428718
Drug: Sleep-promoting intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-promoting intervention with eye patches and earplugs
Trial: 34244327
Drug: Estimated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated treatment cost per injury
Trial: 35607304
Drug: Dexmedetomidine (added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (added to control group treatment)
Trial: 34014975
Drug: Self-medication for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication for headache
Trial: 32366238
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for self-medication
Trial: 35565715
Drug: Hyperhomocysteinemia defined
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperhomocysteinemia defined as levels ≥ 15 µmol/L
Trial: 35565715
Drug: Boys (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boys (mean homocysteine levels 14.1 µmol/L)
Trial: 34691079
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiation
Trial: 35235092
Drug: CBD (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (300 mg; oral)
Trial: 32299734
Drug: Fentanyl and
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl and midazolam (0.1 mg fentanyl and 5 mg midazolam)
Trial: 32299734
Drug: Pethidine and
RxNorm normalized name: pethidine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine and diazepam (25 mg pethidine and 5 mg diazepam)
Trial: 32407272
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg (Maxolon 10 mg, GlaxoSmithKline, Pakistan) administered after rifampicin treatment
Trial: 32789625
Drug: Perceived efficacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived efficacy of daily HIV pill
Trial: 34551471
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 ml saline IV)
Trial: 34323977
Drug: M2-deficient single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2-deficient single replication (M2SR) vaccine
Trial: 34527408
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg fentanyl (group 2)
Trial: 34527408
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (group 1)
Trial: 34527408
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone + 1 μg/kg fentanyl (group 3)
Trial: 33008345
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR), starting dose 2 mg/day, maintenance dose 4-6 mg/day for 50 weeks
Trial: 38314010
Drug: Conventional Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Physical Therapy (CPT)
Trial: 38917366
Drug: Standard antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressants
Trial: 34191185
Drug: Bilirubin (per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilirubin (per 10 µmol/l increase)
Trial: 32091953
Drug: Bilateral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral and unilateral treatments
Trial: 35074399
Drug: RXD2: xylazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXD2: xylazine (0.2 mg/kg) and doxapram (0.2 mg/kg)
Trial: 33330899
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green coffee extract (DGCE) 302 mg
Trial: 36247104
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (2 ml) plus dexmedetomidine 1 μg/kg diluted in 1 ml saline 0.9% (0.5 ml in each tonsil)
Trial: 36247104
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (2 ml + 0.5 ml saline 0.9% per tonsil)
Trial: 35573842
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion group (2 mL/h infusion, 10-min lockout time)
Trial: 35573842
Drug: No background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No background infusion group (6-min lockout time)
Trial: 35573842
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion group
Trial: 33160719
Drug: Haloperidol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.05 or 0.1 mg/kg)
Trial: 35345661
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment group (Buqi Huoxue Decoction + cardiac rehabilitation care)
Trial: 35345661
Drug: TCM +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM + WM group (Buqi Huoxue Decoction + conventional treatment)
Trial: 33975094
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine patch
Trial: 36106759
Drug: Open-labeled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-labeled placebo (OLP) administered as one tablet twice a day for 7 days, followed by 3 weeks of placebo for all patients.
Trial: 38306389
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg)
Trial: 35459970
Drug: Biological determinist
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological determinist condition
Trial: 36477733
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg once daily
Trial: 33331040
Drug: Novel dental
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel dental gel containing 2.6% EDTA
Trial: 34181880
Drug: BNT162b2 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (0.3 mL) via a single intramuscular injection
Trial: 36185306
Drug: Weekly nurse
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly nurse monitoring phone call and educational leaflet
Trial: 33428177
Drug: Sovateltide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovateltide (0.3 µg/kg, intravenous bolus over 1 min, three doses on day 1, day 3, and day 6)
Trial: 39210472
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 3 months
Trial: 36253717
Drug: Lidocaine +
RxNorm normalized name: Lidocaine + Menthol Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine + propofol (Group L)
Trial: 35230203
Drug: ThePaS-I (Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThePaS-I (Therapy Program for Adequate Sexual Behaviors Version 1) - offending-specific skills training
Trial: 33287911
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin 20% (60-g loading dose over 2–3 h, followed by 40–80 g infusion to maintain serum levels at least 30 g/l for 28 days)
Trial: 32362175
Drug: Personalized text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized text message support and a checklist for initiation of antihypertensive medication
Trial: 32667223
Drug: Paediatric Autism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric Autism Communication Therapy
Trial: 33651442
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA 250 mg bid
Trial: 33651442
Drug: 100 mg/mL
RxNorm normalized name: urea 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL intradermal TXA
Trial: 33651442
Drug: 4 mg/mL
RxNorm normalized name: valine 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/mL intradermal TXA
Trial: 34113408
Drug: Periarticular multimodal
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular multimodal cocktail injection without corticosteroids
Trial: 33966891
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCA) with morphine
Trial: 39565030
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotic treatment
Trial: 39565030
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of antibiotic treatment
Trial: 32994107
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of options (no test, 5-gene, then 15-gene)
Trial: 33849683
Drug: Amphetamine 2.5
RxNorm normalized name: amphetamine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine 2.5 mg
Trial: 33387550
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 27 μg clonidine
Trial: 33387550
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 18 μg epinephrine
Trial: 32726445
Drug: Increasing quantities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing quantities of L crispatus
Trial: 32467299
Drug: IL-2 monotherapy
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 monotherapy
Trial: 36410471
Drug: Ripasudil-brimonidine fixed-dose
RxNorm normalized name: brimonidine and ripasudil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ripasudil-brimonidine fixed-dose combination (RBFC)
Trial: 34447181
Drug: aceclofenac +
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aceclofenac + paracetamol
Trial: 33954780
Drug: HPHF meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPHF meal (60 g protein, 40 g fat)
Trial: 33954780
Drug: LPLF meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPLF meal (5 g protein, 5 g fat)
Trial: 37062416
Drug: Nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (125 mg/m2 q1w)
Trial: 34305238
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of bupivacaine, 3 μg of sufentanil, and 10 μg of dexmedetomidine
Trial: 34742002
Drug: Multisystemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic Therapy - Building Stronger Families (MST-BSF)
Trial: 34742002
Drug: Comprehensive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Community Treatment (CCT)
Trial: 33576415
Drug: Integrated Psychosocial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychosocial Group Treatment (IPGT)
Trial: 616391466
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of biperiden and ATD
Trial: 37533380
Drug: Trazpiroben 5
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 5 mg
Trial: 37533380
Drug: Trazpiroben 25
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 25 mg
Trial: 34967147
Drug: Trazpiroben 100
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 100 mg
Trial: 36762852
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy
Trial: 32301670
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment on the upper eyelid
Trial: 32301670
Drug: Normal IPL
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal IPL treatment
Trial: 32232659
Drug: Continuous quadratus
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous quadratus lumborum block (QLB) with 0.25% levobupivacaine 30 ml
Trial: 34491646
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with medication
Trial: 98049290
Drug: Tolbutamide (0.74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (0.74 mg. m<sup>‐2</sup>. min<sup>‐</sup> <sup>1</sup>)
Trial: 98049290
Drug: Tolbutamide (elevated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (elevated both peripheral and portal insulin concentrations)
Trial: 98049290
Drug: Somatostatin (concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (concurrent administration to inhibit tolbutamide-stimulated insulin secretion)
Trial: 33939649
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine citrate infusion (200 mg)
Trial: 32015031
Drug: CSJ148 (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSJ148 (combination of LJP538 and LJP539)
Trial: 32066666
Drug: Bumetanide treatment
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide treatment (0.5 mg twice daily)
Trial: 32066666
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bumetanide treatment)
Trial: 33011399
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of photodynamic therapy (PDT) with scaling and root planing (SRP)
Trial: 33011399
Drug: Two sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sessions of photodynamic therapy (PDT) with scaling and root planing (SRP)
Trial: 33011399
Drug: Three sessions
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sessions of photodynamic therapy (PDT) with scaling and root planing (SRP)
Trial: 36331099
Drug: 0.1% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bromfenac (BF) ophthalmic solution
Trial: 33758395
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy
Trial: 34844575
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) - eight 2-hour sessions
Trial: 35144620
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily for 8 days
Trial: 33386953
Drug: Late-ZOL (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-ZOL (18 months after last Dmab injection)
Trial: 33208696
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: No medication (control group)
Trial: 35169872
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy on alternate days at 33 different sites of the oral mucosa (1 J for 10 s per application point) using a low-power aluminum gallium arsenide laser device (max output power 86.7 mW, wavelength 660 nm)
Trial: 37060420
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy
Trial: 36116481
Drug: Dupilumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (200 mg for bodyweight ≥5 kg to <15 kg; 300 mg for bodyweight ≥15 kg to <30 kg) every 4 weeks plus low-potency topical corticosteroids (hydrocortisone acetate 1% cream) for 16 weeks
Trial: 35802749
Drug: IL-MA injections
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-MA injections once a week
Trial: 35802749
Drug: IL-MA injections
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-MA injections twice a week
Trial: 34809666
Drug: Supervised high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised high-intensity functional exercise programme (HIFE) executed twice weekly over 12 weeks
Trial: 34402360
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined estradiol 0.5 mg + dydrogesterone 2.5 mg
Trial: 34540991
Drug: Carbohydrate beverage
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate beverage administered 2 hours before endoscopy
Trial: 34540991
Drug: Carbohydrate beverage
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate beverage administered 4 hours before endoscopy
Trial: 33848338
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC and 0.12 mg CBD daily (Treatment B)
Trial: 33848338
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg THC and 0.18 mg CBD daily (Treatment C)
Trial: 33848338
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg THC and 0.24 mg CBD daily (Treatment D)
Trial: 33848338
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B vs Treatment D
Trial: 32663286
Drug: App-based mindfulness-meditation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based mindfulness-meditation program (10 min daily for 30 days)
Trial: 32023539
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (5,000 IU daily for 12 weeks)
Trial: 38186268
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy
Trial: 39773838
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs)
Trial: 36058201
Drug: Cortisol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (10 mg hydrocortisone)
Trial: 36151864
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (apremilast 10 mg to 60 mg + phototherapy)
Trial: 33918724
Drug: BMGIM music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMGIM music therapy (8 sessions over 8 weeks)
Trial: 34323984
Drug: Clinician-facing intervention
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-facing intervention providing information about patient analgesic treatment preference and risk of opioid misuse.